Conditions: Recurrent Small-cell Lung Cancer (SCLC) Lung Cancer, Small Cell
Keywords: Bevacizumab Small Cell Lung Cancer (SCLC) Topotecan
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 50
Healthy volunteers: no

Brief summary:
Combination of Hycamtin (topotecan) and Avastin (bevacizumab) could allow killing of both endothelial and neoplastic cells. We postulate that addition of bevacizumab to topotecan will increase delivery of topotecan to tumor cells and may enhance activity of topotecan in patients with previously treated small cell lung cancer and improve progression free survival.

Detailed description:

Arms:
arm 1: Oral topotecan + IV Bevacizumab

Interventions: intervention 1: Oral Hycamtin (topotecan) Capsules + IV Avastin (bevacizumab)
Intervention descriptions: intervention 1: 2.3 mg/m2 daily x 5 oral topotecan and 15 mg/kg IV bevacizumab on day 1 of every 21 days cycle.

Protocol document: